Angiotensin IV analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
=== Thyroxine, iodine and apoptosis === Thyroxine and iodine stimulate the apoptosis of the cells of the larval gills, tail and fins in amphibian metamorphosis, and stimulate the evolution of their nervous system transforming the aquatic, vegetarian tadpole into the terrestrial, carnivorous frog. In fact, amphibian frog Xenopus laevis serves as an ideal model system for the study of the mechanisms of apoptosis.
Interferon enhances the immune response by increasing the expression of genes involved in the antiviral immune response through activation of interferon receptors on the surface of the cell. Potential novel treatments including the NMT inhibitor, has been shown to completely inhibit Lassa (LAS) and Junín (JUN)viral infections in cells based assays. Another host-directed antiviral acts on EPRS1 which in turn acts, in human cells, as a proviral factor in mammarenaviruses infection, including LCMV, JUNV, and LASV, and its inhibition using halofuginon compound, a prolyl domain inhibitor of EPRS1, completely abolishes the viral infection by interrupting viral assembly and budding. PKR has been shown to act as a proviral factor while the inhibition of its kinase activity restricted the virus replication and infectivity.
As Joseph November said in Digitizing Life: The Introduction of Computers to Biology and Medicine, "(Buchanan) wanted the system (Dendral) to make discoveries on its own, not just help humans make them". Buchanan, Lederberg and Feigenbaum designed "Meta-Dendral", which was a "hypothesis maker". Heuristic Dendral "would serve as a template for similar knowledge-based systems in other areas" rather than just concentrating in the field of organic chemistry. Meta-Dendral was a model for knowledge-rich learning systems that was later codified in Tom Mitchell's influential Version Space Model of learning. By 1970, Dendral was performing structural interpretation at post-doc level. Djerassi and his group would take over the program for their own research for a decade. In recent years, Dendral’s influence has extended into modern artificial intelligence systems for chemical structure elucidation. Contemporary projects such as METIS (software) and SpecTUS (2025) continue Dendral’s legacy by applying machine learning to automate GC–MS data interpretation and de novo molecular structure prediction.
In September 2008, Aboitiz Equity Ventures decided to quit the shipping business to focus on its core businesses, namely power and financial services, and announced the sale of its controlling 77% stake in Aboitiz Transport System to KGLI‑NM Holdings, a joint venture between Negros Navigation and Dutch investors, with plans to acquire the remaining shares and potentially delist the company, but due to financing difficulties during the global financial crisis, KGLI‑NM was unable to complete the full buyout, paid only a P100 million option fee, and eventually withdrew its offer in May 2009, terminating the agreement. On December 1, 2010, Aboitiz Equity Ventures sold its transport business to Negros Navigation Co. Inc. (NENACO) for US$105 million, transferring all logistics and shipping operations under new ownership. At the same time, the China–ASEAN Investment Cooperation Fund, a Netherlands-based private equity firm owned by the Government of the People's Republic of China, acquired a controlling stake in NENACO through an equity infusion. In 2012, the company was reorganized and rebranded as 2GO Group Inc. with its brands SuperFerry, SuperCat, and Cebu Ferries merged with Negros Navigation to form 2GO Travel. In 2016, SM Investments Corporation (SMIC) and Chelsea Logistics and Infrastructure Holdings Corp. (owned by Dennis Uy) jointly acquired a major stake in 2GO Group Inc. In 2021, Chelsea Logistics sold its shares to SMIC, making 2GO a full subsidiary of SM Investments Corporation.
Sources: en.wikipedia.org
Ayahuasca is a South American psychoactive decoction prepared from Banisteriopsis caapi vine and a dimethyltryptamine (DMT)-containing plant, used by Indigenous cultures in the Amazon and Orinoco basins as part of traditional medicine and shamanism. The word ayahuasca, originating from Quechuan languages spoken in the Andes, refers both to the B. caapi vine and the psychoactive brew made from it, with its name meaning 'spirit rope' or 'liana of the soul'. Although often portrayed as ancient, ayahuasca likely spread across the western Amazon only within the past few centuries; the first clear written accounts appear in the 17th century. The specific ritual use of ayahuasca was widespread among Indigenous groups by the 19th century. Ayahuasca is traditionally prepared by macerating and boiling B. caapi with other plants like Psychotria viridis during a ritualistic, multi-day process. Ayahuasca has been used in diverse South American cultures for spiritual, social, and medicinal purposes, often guided by shamans in ceremonial contexts involving specific dietary and ritual practices, with the Shipibo-Konibo people playing a significant historical and cultural role in its use. Originally confined to regions of Peru, Brazil, Colombia, and Ecuador, ayahuasca became widespread in Brazil, expanding widely by the mid-20th century through syncretic religions in Brazil.
=== Relationship with Jeffrey Epstein === On January 30, 2026, the United States Department of Justice released a tranche of around 3,000,000 documents from an archive previously collected by the FBI in relation to their investigation into Jeffrey Epstein's various child sex crimes. It revealed that Ariely had a longstanding relationship with Epstein, including having visited him at his New York home on several occasions. One of the documents is an image of an email from Ariely to Epstein, in which he requests the name and email of a "redhead" that Epstein had previously introduced to him. Following claims made about his association with Epstein, Ariely published a response in the student newspaper Duke Chronicle, stating, "...the contact I had with Jeffrey Epstein was infrequent, largely logistical, often mediated by assistants". He also explained that he had met the woman at a conference, assumed she was a colleague of his, and had an intellectual conversation with her, but he did not recall ever meeting her again. The New York Times subsequently reported further on Ariely's relationship with Epstein, including Ariely asking Epstein for funding for a film he was making in 2014, seeking travel tips, and accepting a tour of a Ferrari factory arranged by Epstein. Ariely is named 636 times in the Epstein files, although many of the mentions are in threads of emails where Epstein's assistant scheduled multiple meetings each day.
== Screening == Fasting plasma glucose screening should begin at age 30–45 and be repeated at least every three years. Earlier and more frequent screening should be conducted in at-risk individuals. The risk factors for which are listed below:
Zinc has an electron configuration of [Ar]4s23d10 and is a member of the group 12 of the periodic table. It is a moderately reactive metal and strong reducing agent; in the reactivity series it is comparable to manganese. The surface of the pure metal tarnishes quickly, eventually forming a protective passivating layer of the basic zinc carbonate, Zn5(OH)6(CO3)2, by reaction with atmospheric carbon dioxide. Zinc burns in air with a bright bluish-green flame, giving off fumes of zinc oxide. Zinc reacts readily with acids, alkalis and other non-metals. Extremely pure zinc reacts only slowly at room temperature with acids. Strong acids, such as hydrochloric or sulfuric acid, can remove the passivating layer and the subsequent reaction with the acid releases hydrogen gas. Zinc chemistry resembles that of the late first-row transition metals, nickel and copper, as well as certain main-group elements. Almost all zinc compounds have the element in the +2 oxidation state. When Zn2+ compounds form, the outer shell s electrons are lost, yielding a bare zinc ion with the electronic configuration [Ar]3d10. The filled interior d shell generally does not participate in bonding, producing diamagnetic and mostly colorless compounds. In aqueous solution an octahedral complex, [Zn(H2O)6]2+ is the predominant species. The ionic radii of zinc and magnesium happen to be nearly identical.
The properties of nanoparticles often differ markedly from those of larger particles of the same substance. Since the typical diameter of an atom is between 0.15 and 0.6 nm, a large fraction of the nanoparticle's material lies within a few atomic diameters of its surface. Therefore, the properties of that surface layer may dominate over those of the bulk material. This effect is particularly strong for nanoparticles dispersed in a medium of different composition since the interactions between the two materials at their interface also becomes significant. Nanoparticles occur widely in nature and are objects of study in many sciences such as chemistry, physics, geology, and biology. Being at the transition between bulk materials and atomic or molecular structures, they often exhibit phenomena that are not observed at either scale. They are an important component of atmospheric pollution, and key ingredients in many industrialized products such as paints, plastics, metals, ceramics, and magnetic products. The production of nanoparticles with specific properties is a branch of nanotechnology. In general, the small size of nanoparticles leads to a lower concentration of point defects compared to their bulk counterparts, but they do support a variety of dislocations that can be visualized using high-resolution electron microscopes. However, nanoparticles exhibit different dislocation mechanics, which, together with their unique surface structures, results in mechanical properties that are different from the bulk material.
Sources: en.wikipedia.org
After the riots, the controversial New Economic Policy was launched by Prime Minister Tun Abdul Razak, trying to increase the share of the economy held by the bumiputera. Under Prime Minister Mahathir Mohamad there was a period of rapid economic growth and urbanisation beginning in the 1980s. The economy shifted from being agriculturally based to one based on manufacturing and industry. Numerous mega-projects were completed, such as the Petronas Towers, the North–South Expressway, the Multimedia Super Corridor, and the new federal administrative capital of Putrajaya. In the late 1990s, the Asian financial crisis impacted the country, nearly causing their currency, stock, and property markets to crash; however, they later recovered. The 1MDB scandal was a major global corruption scandal that implicated then-Prime Minister Najib Razak in 2015. The scandal contributed to the first change in the ruling political party since independence in the 2018 general election. In the 2020s, the country was gripped by a political crisis that coincided with health and economic crises caused by the COVID-19 pandemic. This was then followed by an earlier general election in November 2022, which resulted in the first hung parliament in the nation's history. On 24 November 2022, Anwar Ibrahim was sworn in as the 10th Prime Minister of Malaysia, leading a grand coalition government.
Hemoglobin Lepore syndrome is typically an asymptomatic hemoglobinopathy, which is caused by an autosomal recessive genetic mutation. The Hb Lepore variant, consisting of two normal alpha globin chains (HBA) and two delta-beta globin fusion chains which occurs due to a "crossover" between the delta (HBD) and beta globin (HBB) gene loci during meiosis and was first identified in the Lepore family, an Italian-American family, in 1958. There are three varieties of Hb Lepore, Washington (Hb Lepore Washington, AKA Hb Lepore Boston or Hb Lepore Washington-Boston), Baltimore (Hb Lepore Baltimore) and Hollandia (Hb Hollandia). All three varieties show similar electrophoretic and chromatographic properties and hematological findings bear close resemblance to those of the beta-thalassemia trait; a blood disorder that reduces the production of the iron-containing protein hemoglobin which carries oxygen to cells and which may cause anemia. The homozygous state for Hb Lepore is rare. Patients of Balkan descent tend to have the most severe presentation of symptoms including severe anemia during the first five years of life. They also presented with significant splenomegaly, hepatomegaly, and skeletal abnormalities identical to those of homozygous beta-thalassemia. The amount of Hb Lepore in the patients blood ranged from 8 to 30%, the remainder being fetal hemoglobin (Hb F) which is present in minute quantities (typically<1 percent) in the red blood cells of adults. Known as F- cells they are present in a small proportion of overall RBCs.
While chloral hydrate was converted to a different metabolite than chloroform, it was found that it was converted into the more lipophilic molecule 2,2,2-trichloroethanol. This metabolite fit much better with the Meyer–Overton correlation than chloral had. Prior to this, it had not been demonstrated that general anesthetics could undergo chemical changes to exert their action in the body. Chloral hydrate was the first hypnotic to be used intravenously as a general anesthetic. In 1871, Pierre-Cyprien Oré began experiments on animals, followed by humans. While a state of general anesthesia could be achieved, the technique never caught on because its administration was more complex and less safe than the oral administration of chloral hydrate, and less safe for intravenous use than later general anesthetics were found to be.
Portal 2 was released as a standalone game in April 2011 on both computers and consoles. It is considered one of the greatest video games of all time by numerous publications and critics. It received acclaim for its gameplay, pacing, dark humor, writing, the voice work of McLain, Merchant, and Simmons, and its challenging but surmountable learning curve.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.